Related Experiment Video
Updated: Oct 6, 2025
11:19
Correlating Gene-specific DNA Methylation Changes with Expression and Transcriptional Activity of Astrocytic KCNJ10 Kir4.1
Published on: September 26, 2015
8.1K
Novel methylation mark and essential hypertension
1Department of Biotechnology, Maharishi Markandeshwar (Deemed to be) University, Mullana-Ambala, Haryana, 133207, India. mayank.genome@gmail.com.
Journal, Genetic Engineering & Biotechnology
|January 21, 2022
Summary
Essential hypertension (EH) is a complex condition influenced by genetics and environment. Emerging research highlights DNA methylation, including N6-methyladenine (6mA), as a key epigenetic factor in blood pressure regulation and a potential therapeutic target.
Area of Science:
- Epigenetics
- Molecular Biology
- Cardiovascular Research
Background:
- Essential hypertension (EH) is a multifactorial condition and a significant risk factor for cardiovascular, cerebral, and renal disorders.
- While genetic factors are implicated, they do not fully explain blood pressure variability, suggesting the involvement of epigenetic mechanisms.
- DNA methylation, particularly 5-methylcytosine (5mC), is a well-studied epigenetic mechanism, but its role in hypertension is still emerging.
Purpose of the Study:
- To review the current understanding of DNA methylation's role in hypertension.
- To explore the emerging role of N6-methyladenine (6mA) methylation in blood pressure regulation.
- To discuss potential therapeutic targets for hypertension based on epigenetic modifications.
Main Methods:
- Literature review of studies on DNA methylation (5mC and 6mA) in hypertension.
- Analysis of recent findings on the association of aberrant methylation marks with blood pressure regulation.
- Compilation of evidence for epigenetic programming in hypertension.
Main Results:
- Aberrant DNA methylation is increasingly recognized as a crucial factor in hypertension pathogenesis.
- N6-methyladenine (6mA), a recently identified methylation mark in eukaryotes, shows potential relevance to hypertension.
- ALKBH1, a demethylase for 6mA, is emerging as a potential therapeutic target.
Conclusions:
- Targeting both 5-methylcytosine (5mC) and N6-methyladenine (6mA) levels offers a broader perspective on methylation's role in hypertension.
- 6mA levels represent a novel biomarker for hypertension, and ALKBH1 presents a potential therapeutic target for epigenetic programming to prevent hypertension.
Related Concept Videos
01:29Hypertension II: Pathophysiology
133
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
133
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
69
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
69
01:18Hypertension and Regulation of Blood Pressure
3.3K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.3K
01:46Epigenetic Regulation
31.5K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.5K
01:17Phase II Reactions: Methylation Reactions
401
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
401
01:28Hypertension I: Introduction
123
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
123